Vimarsana
Biggest News Aggregation in the World

Page 25 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

FDA Clears Genetic Test for Cancer Risk Assessment - Vimarsana News

FDA Clears Genetic Test for Cancer Risk Assessment

FDA grants first-of-its-kind approval for Invitae's Hereditary Cancers Panel, reforming cancer risk detection.

Kyowa acquiring gene therapy firm Orchard for up to $478M - Vimarsana News

Kyowa acquiring gene therapy firm Orchard for up to $478M

Japanese specialty global pharma Kyowa Kirin Co. Ltd. has agreed to buy out Orchard Therapeutics plc in a $387.4 million cash takeover that could jump $90 million to reach $477.6 million, contingent on the pending U.S. FDA approval of its EU-approved gene therapy, Libmeldy (atidarsagene autotemcel).

Biotech Stocks Facing FDA Decision In October 2023 - Vimarsana News

Biotech Stocks Facing FDA Decision In October 2023

As we step into the year's last quarter, it is worth noting that the FDA has already granted approval to 40 novel drugs in 2023, a significant increase compared to the 26 novel drugs approved during the same period last year.

First Tocilizumab Biosimilar Approved in the United States - Vimarsana News

First Tocilizumab Biosimilar Approved in the United States

The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Source: ajmc.com
Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio - Vimarsana News

Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio

CAMBRIDGE, Mass., October 04, 2023--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that it has raised $35 million in Series B funding, led by Kurma Partners’ Growth Opportunities Fund, with participation from existing investors Seroba Life Sciences and Irish, U.S. and Canadian based family offices and Enterprise Ireland. The funding will enable Shorla to accelerate the growth of its oncology portfolio by advancing its pipeline, bringing therapies to

Source: yahoo.com